Senores Pharmaceuticals Limited — Investor Meet, 03-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Senores Pharmaceuticals reported strong Q1 FY27 financial results: consolidated revenue at 180 Cr (+36% YoY), PAT at 31 Cr (+56% YoY), and EBITDA at 54 Cr (+87% YoY) with 30% margins. Regulated markets revenue surged 42% YoY, while emerging markets grew 30% YoY and generated 18 Cr in operating cash. Management projects FY27 revenue growth of 30-40% and PAT growth of 50-60%, aiming for 2,500-3,000 Cr revenue in 3-4 years. The company doubled its ANDA portfolio to 58 (23 commercialized). IPO funds were strategically reallocated to expand oral solid manufacturing capacity. Management expressed confidence in sustained profitable growth across all segments.